Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 45

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 45
---
 and to the extent the Warrants are exercised, you may experience dilution
to your holdings.

We will not receive any meaningful amount of additional funds upon the exercise of the Pre-Funded Warrants.

Each Pre-Funded Warrant will be exercisable by
means of payment of the nominal cash purchase price upon exercise. Accordingly, we will not receive any or any meaningful additional funds
upon the exercise of the Pre-Funded Warrants.

<div align='center'>20</div>

The Warrants are not exercisable until the Warrant Stockholder Approval; provided, however, that if the Pricing Conditions are met, the Common Warrants will be exercisable upon issuance.

The Warrants will have an assumed exercise price
of $2.455 per share and will be exercisable beginning on the effective date of the Warrant Stockholder Approval; provided, however,
that if the Pricing Conditions are met, the Warrants will be exercisable upon issuance the Initial Exercise Date. The Series A-1 Warrants
will expire on the fifth anniversary of the Warrant Stockholder Approval or Initial Exercise Date, as applicable, and the Series
A-2 Warrants will expire on the 18-month anniversary of the Warrant Stockholder Approval or Initial Exercise Date, as applicable.

While we intend to promptly seek Warrant Stockholder
Approval, if needed, there is no guarantee that the Warrant Stockholder Approval will ever be obtained. If we are unable to obtain the
Warrant Stockholder Approval, the Warrants may have no value.

Regardless of the amount of cash that is raised in this public offering, we will require additional financing in the future to continue as a going concern.

We will not generate sufficient revenues in the
foreseeable future to fund our operations. Accordingly, regardless of the amount of net proceeds that are raised in this offering, we
will require additional financing in the future to continue as a going concern. If we are unable to raise additional capital or generate
sufficient cash from operations to adequately fund our operations, we will, at a minimum, need to curtail planned business activities
to reduce costs, which we expect will harm our ability to execute on our business plan and continue operations.

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Our management will have broad discretion in the
application of the net proceeds from this offering, including for any of the purposes described in the section titled “Use of Proceeds,” and you will not have the opportunity